How to buy Ocugen stock

Ocugen, Inc is a biotechnology business based in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Ocugen employs 15 staff and has a trailing 12-month revenue of around 0.00.

Ocugen share price

Use our graph to track the performance of OCGN stocks over time.

Ocugen shares at a glance

• Key figures

Information last updated 2021-05-08.

52-week range	$0.19 - $16.20
50-day moving average	$8.38
200-day moving average	$4.74
Wall St. target price	$9.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.83

Buy Ocugen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Ocugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ocugen, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocugen financials

Revenue TTM	$42,620
Gross profit TTM	$-5,099,160
Return on assets TTM	-37.3%
Return on equity TTM	-134.01%
Profit margin	0%
Book value	N/A
Market capitalisation	$1.7 billion

TTM: trailing 12 months

Shorting Ocugen shares

There are currently 34.8 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 28.2% up from 27.1 million last month.

There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.

Ocugen's "short interest ratio" (SIR)

Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 22.4 million). Ocugen's SIR currently stands at 1.55. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 1550 shares are currently held short.

However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 180 shares are currently held short) or 0.1901% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 190 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.

Find out more about how you can short Ocugen stock.

Ocugen share dividends

We're not expecting Ocugen to pay a dividend over the next 12 months.

Have Ocugen's shares ever split?

Ocugen's shares were split on a 1:60 basis on 29 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.

Ocugen overview

Ocugen, Inc. , a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Frequently asked questions

• What percentage of Ocugen is owned by insiders or institutions?

  Currently 2.514% of Ocugen shares are held by insiders and 7.578% by institutions.

• How many people work for Ocugen?

  Latest data suggests 15 work at Ocugen.

• When does the fiscal year end for Ocugen?

  Ocugen's fiscal year ends in December.

• Where is Ocugen based?

  Ocugen's address is: 263 Great Valley Parkway, Malvern, PA, United States, 19355

• What is Ocugen's ISIN number?

  Ocugen's international securities identification number is: US67577C1053

• What is Ocugen's CUSIP number?

  Ocugen's Committee on Uniform Securities Identification Procedures number is: 43358V109